Strides Pharma Science Ltd announced that its subsidiary has received approval from the USFDA for its generic version of Theophylline extended-release tablets, used to manage chronic asthma and other respiratory conditions. The tablets, available in 300 mg and 450 mg doses, will be produced at their Bengaluru facility and have a market size of around USD 11.5 million.
Disclaimer : Mymoneytimes implements extreme caution and care in collecting data before publication. Mymoneytimes does not liable for the adequacy, accuracy or completeness of any given information. Hence we are not liable for any kind of direct or indirect loss caused by the use of such information.